Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM-Reference-Cited by-同舟云学术

Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM

Published:2021 Issue:1 Volume:10 Page:45
ISSN:2305-2198
Container-title:Laboratornaya sluzhba
language:en
Short-container-title:Lab. sluzh.

Author:

Langlois M.R.,Nordestgaard B.G.,Langsted A.,Chapman M.,Aakre K.M.,Baum H.,Borén J.,Bruckert E.,Catapano A.,Cobbaert Ch.,Collinson P.,Descamps O.S.,Duff Ch.J.,Eckardstein von A.,Hammerer-Lercher A.,Kamstrup P.R.,Kolovou G.,Kronenberg F.,Mora S.,Pulkki K.,Remaley A.T.,Rifai N.,Ros E.,Stankovic S.,Stavljenic-Rukavina A.,Sypniewska G.,Watts G.F.,Wiklund O.,Laitinen P.

Publisher

Media Sphere Publishing Group

Subject

General Medicine

Reference99 articles.

1. Langlois MR, Chapman MJ, Cobbaert C, Mora S, Remaley AT, Ros E, et al. European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. Clin Chem. 2018;64:1006-1033

2. Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, et al. European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Consensus Panel. Fasting is not routinely required for a lipid profile: Clinical and laboratory implications including agging at desirable concentration cut-points — a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J. 2016;37:1944-1958

3. Langsted A, Kamstrup PR, Nordestgaard BG. High lipoprotein(a) and high risk of mortality. Eur Heart J. 2019;40:2760-2770

4. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

5. Anderson TJ, Grégoire J, Pearson GJ, Barry AR, Couture P, Dawes M, et al. 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemifor the Prevention of Cardiovascular Disease in the Adult. Can J Cardiol. 2016;32:1263-1282

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lipoprotein(a) in the diagnosis of cardiovascular risk. The values of lipoprotein (a) and apolipoprotein B in the adult population of Krasnoyarsk;Russian Journal of Cardiology;2023-07-17